Home » Stocks » RGLS

Regulus Therapeutics Inc. (RGLS)

Stock Price: $0.637 USD 0.029 (4.72%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.660 +0.023 (3.66%) Nov 27, 4:16 PM

Stock Price Chart

Key Info

Market Cap 24.94M
Revenue (ttm) 5.02M
Net Income (ttm) -19.30M
Shares Out 39.16M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.637
Previous Close $0.608
Change ($) 0.029
Change (%) 4.72%
Day's Open 0.614
Day's Range 0.608 - 0.640
Day's Volume 160,300
52-Week Range 0.422 - 1.740

More Stats

Market Cap 24.94M
Enterprise Value 20.74M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 39.16M
Float n/a
EPS (basic) -0.74
EPS (diluted) -0.68
FCF / Share -0.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 997,113
Short Ratio 1.81
Short % of Float n/a
Beta 1.98
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.96
PB Ratio 3.07
Revenue 5.02M
Operating Income -17.56M
Net Income -19.30M
Free Cash Flow -20.76M
Net Cash 4.20M
Net Cash / Share 0.11
Gross Margin -109.81%
Operating Margin -349.54%
Profit Margin -384.20%
FCF Margin -413.24%
ROA -45.03%
ROE -507.19%
ROIC -1,196.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$1.00*
(57.06% upside)
Low
0.50
Current: $0.637
High
1.50
Target: 1.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6.830.070.071.1920.767.6719.5712.7013.798.60
Revenue Growth9388.89%0%-93.97%-94.25%170.69%-60.81%54.09%-7.9%60.32%-
Gross Profit6.830.070.071.1920.767.6719.5712.7013.798.60
Operating Income-16.83-46.76-70.13-81.50-54.76-44.91-17.80-12.57-7.14-15.50
Net Income-18.59-48.71-71.91-81.84-55.75-56.68-18.67-17.41-7.60-15.56
Shares Outstanding17.268.726.274.404.283.673.210.680.01-
Earnings Per Share-1.08-5.59-11.47-18.59-12.96-15.48-5.88-25.44-1,029.88-
Operating Cash Flow-19.82-43.27-58.77-56.88-49.86-39.51-28.33-8.72-15.0612.31
Capital Expenditures0.10-0.02-0.30-0.91-1.36-1.15-0.80-1.15-0.47-1.88
Free Cash Flow-19.72-43.30-59.08-57.80-51.22-40.66-29.13-9.87-15.5310.42
Cash & Equivalents34.1213.9460.0776.1111516011498.1038.14-
Total Debt14.6316.5819.8619.80-23.4011.2810.1310.00-
Net Cash / Debt19.49-2.6440.2256.3111513610387.9728.14-
Assets42.0827.9377.8110114117112310442.88-
Liabilities22.0733.7842.5944.5917.0139.4729.6141.4341.68-
Book Value20.02-5.8535.2256.0812413293.4662.09-41.49-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Regulus Therapeutics Inc.
Country United States
Employees 24
CEO Joseph P. Hagan

Stock Information

Ticker Symbol RGLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RGLS
IPO Date October 4, 2012

Description

Regulus Therapeutics, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.